The poor blood supply to solid tumours introduces many factors that affect the outcome of chemotherapy, one of which is the problem of drug delivery to poorly vascularized regions of tumours. Whereas poor drug penetration has been recognized as a contributing factor to the poor response of many solid tumours, the question of drug penetration through multicell layers has not been thoroughly addressed, largely because of restrictions imposed upon these studies by the requirement for either radiolabelled or naturally fluorescent compounds. The aim of this study is to describe modifications made to a recently published assay that broadens the scope for assessing drug penetration during the early stages of drug development and to characterize the ability of various drugs to penetrate multicell layers. DLD-1 human colon carcinoma cells were cultured on Transwell-COL plastic inserts placed into 24-well culture plates so that a top and bottom chamber were established, the two chambers being separated by a microporous membrane. Drugs were added to the top chamber at doses equivalent to peak plasma concentrations in vivo and the rate of appearance of drugs in the bottom chamber determined by high-performance liquid chromatography (HPLC). Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 ± 12.1 gm thick) with t1,2 values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-,-en-a-ol (EO9) and doxorubicin through multicell layers was significantly slower (t1,2 = 4.62 and 13.1 h respectively). Inclusion of dicoumarol increases the rate of E09 penetration, whereas reducing the oxygen tension to 5% causes a reduction in tirapazamine penetration through multicell layers, suggesting that the extent of drug metabolism is one factor that determines the rate at which drugs penetrate multicell layers. The fact that E09 does not readily penetrate a multicell layer, in conjunction with its rapid elimination in vivo (tl,2 < 10 min), suggests that E09 is unlikely to penetrate more than a few ,um from a blood vessel within its pharmacokinetic lifespan. These results suggest that the failure of E09 in the clinic is due to a combination of poor drug penetration and rapid elimination in vivo.
The ultimate objective of any systemic therapy for cancer is to eradicate all tumour cells whether it is by direct cytotoxicity or by modifying the malignant phenotype (Schipper et al, 1996) . In order to achieve this objective, it is essential that anti-cancer agents reach all clonogenic cells within the tumour at the concentrations that are required for a therapeutic effect. The blood supply to many solid tumours is known to be both inadequate and intermittent, resulting in regions of tumours that are chronically and transiently hypoxic (Coleman, 1988; Vaupel et al, 1989) . Hypoxia by itself, or in conjunction with other features of the tumour microenvironment such as low extracellular pH and reduced cell proliferation rates, etc., can adversely affect the efficacy of both radiotherapy and chemotherapy (Thomlinson and Gray, 1955; Denekamp, 1986) . In terms of chemotherapy, cytotoxic drugs have to diffuse from the vascular compartment and penetrate through several layers of cells in order to reach cells that reside some distance away from a blood vessel. Drug penetration barriers exist for a number of clinically used anti-cancer drugs, and the failure of drugs to penetrate throughout the tumour within their pharmacokinetic lifespan has been recognized as a contributing factor towards the poor response of many solid tumours to chemotherapy (Goldacre and Sylvdn, 1962; Kerr and Kaye, 1987; Durand, 1989; Simpson-Herren and Noker, 1991) . Multicellular spheroids (Sutherland and Durand, 1976; Sutherland, 1988) have been instrumental in the study of drug diffusion through multicell layers, and drug penetration barriers have been identified for drugs such as doxorubicin, methotrexate, m-AMSA, ara-C, vinblastine and vincristine (Sutherland et al, 1979; West et al, 1980; Wilson et al, 1981; Nederman and Carlsson, 1984; Erlanson et al, 1992) .
Whereas the ability to penetrate several layers of cells is a desirable property of all systemic-based anti-cancer therapies, it is particularly relevant to a class of compounds known as bioreductive drugs. These compounds are designed to kill cells preferentially within the hypoxic tumour microenvironment (Sartorelli, 1988; Workman and Stratford, 1993) and the ideal bioreductive drug should be administered as an inactive prodrug that is only activated under low-oxygen conditions by one or two electron reductases. An essential prerequisite characteristic for an effective bioreductive drug is that the parent compound must diffuse through the aerobic fraction of cells in order to reach the target. With the exception of early studies using nitroimadazole-based radiosensitizers (Chapman et al, 1981 Garrecht and Chapman, 1983; Franko, 1985; Rasey et al, 1985) , relatively few studies have focused on the ability of bioreductive drugs to penetrate through several layers of cells. This is due largely to the fact Stirrer bioreductive indoloquinone compound 5-aziridino-3-hydroxymethyl-i -methyl-2-[ 1 H-indole-4,7-dione] prop-4-en-ox-ol (EO9), which, despite promising activity in preclinical models (Hendriks et al, 1993) , has proved disappointing in the clinic . Studies demonstrating that spheroids are more resistant than monolayers to E09 suggest that drug penetration barriers may exist and this study provides experimental evidence to support the hypothesis that the failure of E09 in the clinic is due to poor penetration into tumours, in conjunction with rapid elimination kinetics in vivo. Cell culture conditions DLD-1 human colon carcinoma cells (Dexter et al, 1979) were routinely maintained at 37°C as monolayer cultures in RPMI-1640 culture medium containing 25 mM HEPES buffer (Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum (Life Technologies), sodium pyruvate (1 mm, Life Technologies,), penicillin-streptomycin (100 IU ml-':100,g ml-', Life Technologies), L-glutamine (1 mm, Life Technologies).
MATERIALS AND METHODS
that compounds have had to be either naturally fluorescent (such as doxorubicin) or radioactively labelled in order to detect penetration into cellular masses. In the early stages of drug development, however, radioactively labelled or fluorescent compounds are rarely available and, consequently, the question of drug penetration has not been thoroughly addressed for the majority of compounds.
Recently, an assay has been developed that has broadened the scope for studying drug penetration during the early stages of preclinical drug development (Cowan et al, 1996) . The assay is based upon the ability of drugs to cross a microporous membrane that supports a multicell layer. Routine analytical techniques [e.g. high-performance liquid chromatography (HPLC)] can be used to measure drug (and/or metabolite) concentrations, making the study of drug penetration a feasible proposition for most laboratories involved in preclinical drug development. The principal objective of this study is to describe and characterize a modified version of the assay published by Cowan et al (1996) and to illustrate the potential significance of this assay by evaluating the ability of selected bioreductive and standard anti-cancer drugs to penetrate multicell layers. Particular attention has been paid to the Growth characteristics of DLD-1 cells in Transwell culture vessels A total of 2.5 x 105 cells in 200 ,ul of RPMI-1640 culture medium was added to the top chamber of Transwell-COL plastic insert (Figure 1 , Corning Costar, High Wycombe, UK). The top and bottom chambers were separated by a collagen-coated, microporous membrane (pore size 0.4 gm, diameter 6.5 mm, surface area 0.33 cm2). Transwell vessels were incubated at 37°C for 3 h to allow cells to attach to the membrane before the addition of 2 ml of RPMI-1640 to the bottom chamber. Cells were incubated at 37°C in an atmosphere containing 5% CO2 for up to 8 days with daily changes of medium in both upper and lower chambers. At various time points, Transwell inserts were removed, fixed in Bouin's fluid for 1 h and washed in 70% ethanol overnight. The membrane was detached from the plastic insert, embedded in paraffin wax and sectioned (5 ,um) using a Leitz rotary microtome (Leica UK, Milton Keynes, UK). Sections were stained with haematoxylin and eosin according to standard protocols, and the average thickness of the multicell layer determined by a Seescan image analyser (Seescan, Cambridge, UK). Three separate Transwells per time point were sectioned and the thickness of each multicell layer was determined on five sections from each Transwell (20 measurements per section). Walton and Workman, 1993; Hodgkiss et al, 1995) . In all cases, the final DMSO concentration was < 0.2%. The Transwell was then inserted into one well of a 24-well plate containing 600 gt of medium and incubated at 37°C. At various time intervals thereafter, 500,l of medium was removed from the bottom chamber and added to I ml of acetonitrile, mixed and stored at -20°C until required for analysis. The insert was then transferred to a different well on the culture plate containing 600,l of fresh medium. This procedure was repeated throughout the duration of the experiment. At all stages of the process, medium in the bottom chamber was agitated using a small magnetic stirrer. In the case of E09, drug penetration was assessed on days 1, 4 and 8 of the growth curve in order to determine the relationship between the thickness of the multicell layer and the rate of penetration. In the case of tirapazamine, NITP and doxorubicin, drug penetration was determined on day 4 of the growth curve. All experiments were repeated independently on three occasions. The stability of test compounds under the experimental conditions used (i.e. tissue culture medium at 37°C for 3 h) was determined according to the procedures described above.
Sample analysis
Samples were evaporated down to 500 tl under vacuum using a RC 10. 10 centrifugal evaporator (Jouan, Ilkeston, UK). A further Data analysis Drug concentrations in each sample were summated such that a graph of total drug penetration against time could be plotted. For example, drug concentrations at time point 1 were added to drug concentrations at time point 2 in order to obtain the total drug concentration in the lower chamber at time point 2. Drug concentrations in the lower chamber were calculated from the ratio of peak areas for samples divided by the peak area of drug in the top chamber at t = 0. Drug penetration through the multicellular layer was assumed to be a first-order process. Half-lives and penetration rate constants were calculated by standard pharmacokinetic procedures (Rowland and Tozer, 1989) , normally used for the absorption of drug into the plasma from an extravascular site with Ae-Kp representing the movement of drug through the multicell layer. Therefore the equation to describe the drug appearing in the bottom chamber as a function of time is the monoexponential equation:
where Cl = concentration of drug in lower chamber, A = 100% penetration and Kp = penetration rate conbtant.
Kp is calculated from the per cent penetration vs time data using the method of residuals and is equivalent to the absorption rate constant. Penetration half-lives (t,12p) are calculated from the equation t1,2p = 0.693/Kp. Percent penetration was calculated as the drug concentration measured in lower chamber/drug concentration expected if all the administered drug penetrated through the membrane.
Influence of dicumarol on the penetration of E09
DLD-1 cells were cultured in Transwell-COL inserts for 4 days (thickness of the multicell layer was 45 ± 5.2 ,um). E09 was added to the top chamber at a final concentration of 10 gM as described above in the presence or absence of dicoumarol (200 gM). In studies using dicoumarol, medium in the bottom chamber also contained dicoumarol (200 gM). The change in E09 concentration in the lower chamber was determined as described above.
Influence of oxygen tension on the rate of penetration of tirapazamine DLD-1 cells were cultured in Transwell-COL inserts as described above (thickness of multicell layer was 50 ± 5.6 im). Culture plates were then transfered to an incubator supplied with 5% oxygen, 5% CO2 and 90% nitrogen (BOC, Manchester, UK) for 3 h before the addition of tirapazamine (55 gM, which represents peak plasma levels in humans, Graham et al, 1997) to the top chamber. The appearance of tirapazamine in the lower chamber was determined as a function of time as described above. For the purpose of comparison, the penetration of tirapazamine through DLD-1 multicell layers cultured in an atmosphere containing 5% CO2/95% air was also determined. (Figure 2 ). There was a rapid increase in the thickness of cell layers between days 1 and 4, after which the rate of growth of the multicell layer slows down. As multicell layers increased in thickness, cells growing on or near the membrane became elongated and polarized, whereas cells further away from the membrane adopted a flattened appearance ( Figure  3) . No visible regions of necrosis existed ( Figure 3 ) and no binding of NITP could be detected by antibodies to theophylline throughout the section, indicating the absence of hypoxic cells (data not shown).
Penetration of drugs through multicell layers
The penetration of tirapazamine and doxorubicin across Transwell membranes in the presence and absence of DLD-1 cells (50.9 ± 12.1 ,um thick) is presented in Figure 4 . In the absence of cells, both tirapazamine and doxorubicin rapidly crossed the membrane with half-lives of 0.092 and 0.178 h respectively (Table 1 ). In the presence of DLD-1 multicell layers, the penetration of tirapazamine through the cell layer was significantly greater than that of doxorubicin with t 12 values of 1.36 and 13.1 h respectively (Table   1 ). Only the parent compounds were visible on HPLC traces and no metabolites were detected. Both compounds were stable (< 5% breakdown) for the duration of this experiment. The penetration of tirapazamine, NITP, E09 and doxorubicin through multicell layers is presented in Figure 5 . Each drug evaluated penetrated through DLD-1 multicell layers (50 jim thick) at different rates ( Figure 5 and Table 1 ). Half-lives were 1.36, 2.38, 4.62 and 13.1 h for tirapazamine, NITP, E09 and doxorubicin respectively (Table 1) . No metabolites were detected. E09 was relatively stable at 37°C in tissue culture medium at pH 7.5 with a t 12 value of 6.5 h (Phillips et al, 1992) .
Influence of the thickness of the multicell layer on the rate of E09 penetration Influence of oxygen tension and dicoumarol on the penetration of tirapazamine and E09
Reducing the oxygen tension to 5% oxygen causes a significant reduction in the rate of tirapazamine penetration (Kp = 0.26 h-', t,,2 = 2.66 h, Table 3 ) compared with the rate of penetration in an atmosphere containing 20% oxygen (Kp = 0.489 h-', t 12 = 1.42 h, Table 3 ). In the case of E09 (Table 3) , the inclusion of dicoumarol in both the upper and lower chambers of the Transwell apparatus results in a modest increase in the rate of drug penetration (t 12 = 2.7 ± 0.63 h) compared with the rate of E09 penetration in the absence of dicoumarol (t12 = 3.6 ± 0.41 h). 
DISCUSSION
The problem of poor drug delivery to viable cells in avascular regions of solid tumours has been recognized as a contributing factor to the lack of activity of currently available anti-cancer drugs against the majority of solid tumours (Keyes et al, 1985; Sartorelli, 1988) . Although this fact is generally accepted, the question of drug penetration into cellular masses has not received the intense investigation it merits, largely because of practical and technical difficulties inherent in the methods used to evaluate drug penetration. The question of drug penetration is vital for compounds such as bioreductive drugs but good diffusion throughout tumours would be a highly desirable characteristic for any systemic-based therapy of cancer. The assay initially described by Cowan et al (1996) and modified in this paper is technically simple and versatile, thereby broadening the scope for conducting drug penetration studies early on in drug development. The methodology described in this paper differs from that of Cowan et al (1996) in several key areas, details of which are outlined British Journal of Cancer (1998) 77(12) below. First, the assay has been miniaturized so that valuable drug stocks can be conserved. Second, the model described by Cowan et al (1996) does not mimic the aerobic fraction of cells as the multicell layer used contains a central necrotic core. Drugs would have to diffuse through an aerobic fraction into the necrotic core and then out the other side of the necrotic core and through another aerobic fraction of cells before crossing the microporous membrane. The complexity of this model introduces several problems, particularly as bioreductive drugs, for example, would be activated within the hypoxic region, leading to an underestimation of drug penetration. In our opinion, the key question is whether or not the drug actually penetrates through the aerobic fraction of cells as the original, inactive prodrug, and therefore this assay uses multicell layers that mimic the aerobic fraction. Third, no soft agar has been included in the upper chamber as described by Cowan et al (1996) . Soft agar was initially added to the upper chamber to prevent convection currents but its inclusion significantly reduces the rate of drug penetration through microporous membranes that have no cells attached. Finally, standard pharmacokinetic parameters have been applied to the analysis of drug penetration data as opposed to Fick's second law of diffusion. In our opinion, the use of pharmacokinetic parameters is more relevant, as diffusion is not the only mechanism by which drugs cross multicellular layers (Kerr and Kaye, 1987) . In addition, as the rate of penetration into a tumour will depend upon the concentration of drug in the blood and the rate of elimination from the body, it may be possible to predict the extent of drug penetration into tumours based upon knowledge of the drug's pharmacokinetics in vivo and the rate of penetration through multicell layers in vitro. The results of this study demonstrate that penetration across multicell layers is a first-order process and the pharmacokinetic parameters generated in vitro (gm) could be directly compared with pharmacokinetic parameters in vivo to obtain an indication of whether a drug will reach the tumour microenvironment within its pharmacokinetic lifespan.
In the case of bioreductive drugs, the question of drug penetration is paramount as failure of the parent compound to penetrate through the aerobic fraction of tumour cells into hypoxic regions of tumours (within the pharmacokinetic lifespan of the drug in vivo) will severely limit the efficacy of the drug. Estimates of the aerobic fraction vary and are difficult to define precisely as gradients of oxygen tension exist within tumours, the extent of which varies as a function of distance from a supporting blood vessel (Helminger et al, 1997) . Gradients of oxygen tension have been demonstrated within the viable rim of multicellular spheroids (Sutherland et al, 1986) and drugs have to penetrate approximately 200-300,m (depending on the cell line) in order to reach the central necrotic region. It is reasonable to assume therefore that drugs would have to penetrate at least 50 ,um from a blood vessel or into a spheroid in order to reach the target. Using a multicell layer of 50,m thickness, the assay was validated using drugs whose penetration properties are known. In the case of tirapazamine, for example, preferential DNA damage to cells in hypoxic regions of squamous cell carcinoma (SCCVII) tumours was observed using a combination of cell sorting and comet assays (Olive, 1995) . NITP is detectable in tissues using antibodies raised against theophylline, and good evidence exists to show that NITP binds preferentially to cells that reside close to the necrotic regions of mammary CaNT tumours (Hodgkiss et al, 1995) . Both compounds readily penetrate DLD-1 multicell layers, although penetration of tirapazamine is more rapid than NITP under standard cell culture conditions ( Figure 5 ). In contrast to tirapazamine and NITP, significant drug penetration barriers are known to exist for doxorubicin (Sutherland et al, 1979) and this is reflected in the poor rate of penetration through DLD-1 multicell layers presented in Figure 4 .
A number of factors will influence both the delivery of drugs to tumours and transcellular drug transport, details of which have been reviewed elsewhere (Kerr and Kaye, 1987) . Preliminary studies in this paper demonstrate that cellular metabolism is one factor that influences the penetration of drugs accross multicell layers (Table  3 ). In the presence of dicoumarol, which is a potent inhibitor of DT-diaphorase, the rate at which E09 penetrates a multicell layer increases compared with E09 alone. These results suggest that the penetration of E09 into tumours with high DT-diaphorase activity may be impaired as a result of increased drug metabolism. It should be stressed that the activity of DT-diaphorase in DLD-1 cells (546 ± 75 nmol min-' mg-' ; Collard et al, 1995) is significantly higher than the activity of DT-diaphorase activity in human tumours (Malkinson et al, 1992) , and further studies are warranted to determine the effect of drug metabolism in cell lines that have a broader range of DT-diaphorase activity. In the case of tirapazamine, the rate of drug penetration is dependent upon the oxygen status of cultures. As oxygen tension is reduced, the rate of drug penetration decreases, presumably because of increased tirapazamine metabolism (Koch, 1993) . It is not known whether drug metabolism is the rate-limiting step as other factors such as the morphology of cells (i.e. the presence of tight junctions between cells), pH gradients, physicochemical properties of drugs such as lipid solubility, etc. could also play a role. These questions are beyond the scope of this paper and are currently under investigation.
Although the identification of the rate-limiting process that determines drug penetration will give useful information to guide future drug development, the principal objective of this paper is to determine not how currently available drugs get there but whether they do get to the target. As the rate of drug penetration through cell layers will be both concentration and time dependent, pharmacokinetic parameters are likely to play a major role in determining the extent of drug penetration from the vasculature in vivo. In mice, both tirapazamine and NITP have plasma t,2P of 26.5 min and between 20 and 30 min (depending on vehicle and route of administration) respectively (Workman and Walton, 1993; Hodgkiss et al, 1995) . As both drugs have been shown to either damage DNA or bind to cells within the hypoxic tumour microenvironment, the combination of these pharmacokinetic parameters together with the inherent ability to penetrate rapidly through multicell layers suggests that these characteristics form a good guideline for predicting whether other drugs will reach the tumour microenvironment. Other drugs that have similar pharmacokinetic parameters and drug penetration rates through DLD-1 multicell layers would be expected to penetrate through several layers of cells in vivo. In humans the plasma t1/2 value of tirapazamine is longer (46.6 ± 9.53 min; Graham et al, 1997) than in experimental models, suggesting that penetration into the hypoxic microenvironment of solid tumours is likely.
The significance of both pharmacokinetic parameters and drug penetration properties is illustrated in the case of E09. E09 is a bioreductive indoloquinone compound that is activated by the enzyme DT-diaphorase [NAD(P)H:quinone acceptor oxidoreductase, EC 1.6.99.21 to a DNA-damaging species and is preferentially cytotoxic towards DT-diaphorase-rich cells in vitro under aerobic conditions (Walton et al, 1991; Robertson et al, 1994; Smitkamp-Wilms et al, 1996) . The compound was selected for clinical evaluation under the auspices of the EORTC, although no activity against non-small-cell lung cancer (NSCLC), breast, colorectal, pancreatic and gastric cancers was reported in phase II clinical trials (Dirix et al, 1996; Pavlidis et al, 1996) . A possible explanation for the lack of clinical activity stems from the fact that E09 does not penetrate multicell layers as efficiently as tirapazamine or NITP ( Figure 5 ). This result, in conjunction with the fact that E09 is rapidly eliminated from the body in both rodents and humans, with plasma half-lives of 3 and 10 min respectively (Workman et al, 1992; Schellens et al, 1994) , suggests that therapeutic levels of E09 are unlikely to penetrate more than a few microns from a blood vessel within its pharmacokinetic life span.
Poor drug delivery to tumours may therefore be the major factor in explaining the disappointing clinical outcome of E09 as opposed to pharmacodynamic problems. In mice, direct intratumoral injection of E09 resulted in preferential anti-tumour activity against DT-diaphorase-rich tumours, suggesting that, if E09 can be efficiently delivered to tumours, it may be possible to exploit the differences that exist in DT-diaphorase activity in human tumours (Malkinson et al, 1992; Matthew et al, 1996) . In terms of future drug development, either improving the delivery of E09 or developing analogues of E09 that retain the desirable properties of E09 (i.e. bioactivation by DT-diaphorase) but have better pharmacological properties in terms of drug penetration and pharmacokinetics are two ways of addressing the problem (Phillips, 1996) .
In conclusion, this study has described and validated an assay that addresses the critical question of whether or not cytotoxic drugs are able to penetrate into avascular regions of solid tumours. Based upon knowledge of the rate of penetration through multicell layers and pharmacokinetic parameters in vivo for drugs whose penetration properties are known (i.e. tirapazamine, NITP and doxorubicin), it may be possible to predict whether or not novel compounds are able to penetrate into the tumour microenvironment. It should be stressed, however, that penetration into avascular regions of tumours will not guarantee efficacy, as cells in this environment are likely to have different pharmacodynamic characteristics from cells that reside close to blood vessels. Nevertheless, the question of penetration into poorly perfused regions of tumours is important for all systemic-based therapeutic approaches directed against the cancer itself. With minor modifications to the assay, the question of whether or not therapeutic approaches such as antisense, gene therapy, monoclonal antibodies or inhibitors of cell signalling pathways can penetrate into the microenvironment of a tumour within their pharmacokinetic lifespans can be determined. The assay described by Cowan et al (1996) , together with the modifications made to the assay described in this paper, therefore provide a quantitative method for assessing drug penetration during preclinical anti-cancer of drug development. 
